Table 2:

Example predictions from the thematic task forces

Task Force	Statements
Task Force 1: Cancer Etiology	At UCSF in 2030, we will understand how genes elicit complex phenotypes. At UCSF in 2030, we will generate hypothesis-driven data/sample collection. At UCSF in 2030, we will use mechanisms of rare/unique cancers to inform how to target disease. At UCSF in 2030, we will broaden the type of mechanistic questions we are able to answer. At UCSF in 2030, there will be greater understanding of how social determinants effect behavior and biology (i.e., how environmental and social factors ‘get under the skin’).
Task Force 2: Preventing Cancer	At UCSF in 2030, risk prediction and cancer screening will be available, accessible, and effective for all, particularly underrepresented and minority populations (e.g., with the development of prediction models based on polygenic risk scores for non-European ancestry populations) as well as specific subgroups (e.g., lung cancer screening guidelines for non-smokers). At UCSF in 2030, commercialization of cancer early detection with genomic tools (e.g., direct to consumer tests, ctDNA, liquid biopsy, imaging) will become more common and require better understanding of both positive and negative impacts. At UCSF in 2030, cancer care will be coordinated, and clinicians and health care providers have the requisite expertise to deliver specific screening regimens (e.g., addressing preventive genomics). At UCSF in 2030, effective communication strategies will be in place with members of all populations within the catchment areas of comprehensive cancer centers to improve understanding and uptake of cancer prevention practices.
Task Force 3: Detecting and Diagnosing Cancer	At UCSF in 2030, patient data will be collected from multiple sources and layered to determine risk and response. At UCSF in 2030, multimodality imaging data will be collected from multiple sources combined and analyzed using advanced Artificial Intelligence (AI) approaches to provide diagnostic prognostic and predictive information. At UCSF in 2030, information from existing biomarkers will be further enhanced by additional information
Task Force 4: Developing Cancer Cures	At UCSF in 2030, we will be developing and testing highly individualized therapy based on a comprehensive understanding of the biology of the tumor, the contributory features of the patient, and a comprehensive understanding of how the intervention being developed interacts with host and environment. At UCSF in 2030, we will undertake a comprehensive multi-dimensional evaluation of every patient’s cancer, including an understanding of the comprehensive genomic and immunologic characteristics of a cancer, the role of tumor heterogeneity, cancer plasticity, and microenvironment. At UCSF in 2030, the biologic, social, and environmental context of the patient (host) will be an integral component of the treatment paradigm. At UCSF in 2030, outcomes and their determinants, including symptom science (including survivorship), toxicity, patient-reported outcomes, measuring residual disease, non-invasive monitoring, and the development of resistance, both innate and adaptive, will be incorporated into study design. At UCSF in 2030, efficient, rapid testing of novel agents and therapeutic approaches will be developed, leveraging pre-clinical modeling and testing, and large throughput screening.
Task Force 5: Delivering Health Care to All	At UCSF in 2030, Health Outcomes research will focus on measuring, monitoring, evaluating, and improving health outcomes across the cancer control continuum, with a goal of assuring that all people receive timely, affordable, and high-quality care, regardless of who they are, where they live, or where they get their care. At UCSF in 2030, cancer research training programs will emphasize new skills in team science and transdisciplinary approaches, engaging a diverse cohort of trainees both in the United States and globally. At UCSF in 2030, the population of cancer survivors treated at the HDFCCC (and, more generally, in California) will be not only larger, but more diverse, and will have more complicated needs.
Task Force 6: Developing Tools to Study Cancer	At UCSF in 2030, rich data sources will be integrated to inform a multidimensional view of each cancer case. At UCSF in 2030, new technologies will be developed and deployed in the context of integrated, problem-focused research communities. At UCSF in 2030, custom data analysis, algorithm design, and programming will be widely available to researchers. At UCSF in 2030, there will be institutional support to offset the high risk inherent to projects that push the envelope of technology.